![cells](https://nocamels.com/wp-content/uploads/2022/02/cells-350x233.jpg)
Pfizer Extends Partnership With Israeli Drug Development Firm CytoReason
CytoReason built a machine learning platform that can quantify a person’s immune system in order to better understand disease responses.
February 15, 2022
![CytoReason's office in Tel Aviv. Courtesy](https://nocamels.com/wp-content/uploads/2019/05/CytoReason-door-350x263.png)
CytoReason Teams Up With Merck KGaA On Cancer Drug Development
CytoReason will profile one of the German multinational science and technology company's leading immuno-oncology drugs.
October 21, 2021
![Illustration of cells.](https://nocamels.com/wp-content/uploads/2020/02/Depositphotos_11260302_l-2015-350x263.jpg)
Israel’s CytoReason Launches AI Drug Discovery Platform In Japanese Market
Israeli AI company Cytoreason develops computational disease models of the human immune system for discovery and clinical drug development.
September 30, 2021
![A high magnification micrograph of cryptitis in a case of Crohn's disease. By Nephron - Own work, CC BY-SA 3.0, https://commons.wikimedia.org/w/index.php?curid=8697328](https://nocamels.com/wp-content/uploads/2021/05/IBD-350x265.jpg)
Israeli Biotech Startup CytoReason Teams Up With Swiss Pharma Firm Ferring For IBD Drugs
CytoReason said it plans to present insights on the top drug targets to provide new therapeutic options for IBD patients.
May 25, 2021
![CytoReason's David Harel, left, and Professor Shai Shen-Orr. Courtesy](https://nocamels.com/wp-content/uploads/2019/05/Dudi-and-Shai-1-350x263.jpeg)
Israeli Biotech Startup Combines Immunology, AI To Help Develop Better Drugs
Founded in 2016, CytoReason already has partnerships with top global pharmaceutical companies.
May 14, 2019
![Cancer Cells. Photo via DepositPhotos](https://nocamels.com/wp-content/uploads/2018/10/cancercells-350x197.jpg)
Data-Powered Drug Discovery Startup CytoReason Signs Deal With Pfizer
The company's propriety platform combines scientific and experimental data for immune system simulations applicable to cancer immunotherapy, and autoimmune, neurodegenerative and infectious disease research.
January 08, 2019